New obesity drug candidate enters first human safety tests
NCT ID NCT07654972
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This early-stage study tests an experimental drug called LY4174794 in 108 healthy volunteers who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it, not to measure weight loss. Participants will receive either the drug or a placebo and be monitored for about 7 to 11 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON Early Phase Services, LLC
San Antonio, Texas, 78232, United States
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4174794 (an experimental drug)
What this could lead to
If successful, this could lead to a new medication for weight management in people with obesity or overweight.
What could go wrong
This is a very early Phase 1 trial with only 108 participants, focused on safety, not weight loss. The drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.